Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03535350 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

StatusCompleted
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Final enrollment: 27 participants (planned 36)
    • Study completion date changed from estimate of Oct 30, 2026 to Apr 4, 2023
  2. Study completion pushed from Dec 30, 2025 to Oct 30, 2026
    • Eligibility criteria expanded, about 30 words
  3. Study completion date: Jun 30, 2025 to Dec 30, 2025v20
  4. Primary completion date changed from estimate of Dec 31, 2024 to Apr 4, 2023v19
  5. Primary completion date: Jun 30, 2024 to Dec 31, 2024
    • Study completion date: Dec 31, 2024 to Jun 30, 2025
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Primary completion date: Dec 31, 2023 to Jun 30, 2024v17
  2. Primary completion date: Jun 2023 to Dec 31, 2023
    • Study completion date: Dec 2023 to Dec 31, 2024
    v16
  3. Primary completion date: Nov 2022 to Jun 2023
    • Study completion date: Dec 2022 to Dec 2023
    v15
  4. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jun 2022 to Nov 2022
    • Site details revised
    v14
  5. Primary completion date: Dec 2021 to Jun 2022v13
  6. Primary completion date: Sep 2021 to Dec 2021
    • Study completion date: Dec 2021 to Dec 2022
    • Site contact updated
    • Study description expanded, about 2 words
    v12
  7. Start date: Aug 20, 2018 to Aug 24, 2018
    • Study description expanded, about 33 words
    v11
  8. Primary completion date: Apr 1, 2021 to Sep 2021
    • Study completion date: Aug 1, 2021 to Dec 2021
    v10
  9. Primary completion date: Nov 1, 2020 to Apr 1, 2021
    • Study completion date: Feb 1, 2021 to Aug 1, 2021
    v9
  10. Site contact updatedv8
  11. Primary completion date: Jun 1, 2020 to Nov 1, 2020
    • Study completion date: Dec 1, 2020 to Feb 1, 2021
    v7
  12. Primary completion date: Dec 1, 2019 to Jun 1, 2020
    • Study completion date: Dec 1, 2019 to Dec 1, 2020
    v6
  13. Primary and study completion dates: Apr 1, 2019 to Dec 1, 2019v5
  14. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Primary completion date: Dec 2019 to Apr 1, 2019
    • Study completion date: Dec 2020 to Apr 1, 2019
    • Start date changed from estimate of Nov 2018 to Aug 20, 2018
    • Site details revised
  15. Re-verified, no change to tracked fieldsv3
  16. Start date: Jul 9, 2018 to Nov 2018v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Safety of combination of ibrutinib and radiation at various dose levels in unmethylated o6-methylguanine-DNA-methyltransferase (MGMT) glioblastoma and study of ibrutinib, temozolomide, and radiation combination therapy in methylated MGMT glioblastoma.
Trial Details
NCT Number NCT03535350
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Glioblastoma
Related terms Brain Neoplasms, Glioblastoma
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov